Literature DB >> 6205075

Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.

D A Fox, R E Hussey, K A Fitzgerald, O Acuto, C Poole, L Palley, J F Daley, S F Schlossman, E L Reinherz.   

Abstract

By using a murine monoclonal antibody produced against an IL 2-dependent human T cell line, we defined a T lineage-specific molecule, termed Ta1, that is expressed strongly on activated T lymphocytes of both the T4 and T8 subsets, as well as on T cell lines and clones, but only weakly on a fraction of resting T cells. SDS-PAGE analysis of immunoprecipitates from 125I-labeled, activated T cells demonstrates a single major band of apparent m.w. 105 KD under both reducing and nonreducing conditions. Unlike anti-IL 2 receptor antibodies, anti-Ta1 does not inhibit T cell proliferative responses to mitogen, antigen, or IL 2-containing medium. Moreover, anti-Ta1 has no effect on T cell-mediated cytotoxicity. Ta1 appears to be a novel human T cell-specific activation antigen that may serve as a useful marker of T cell activation in human disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205075

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Serial studies of evoked potentials and circulating lymphocyte subsets for multiple sclerosis: attempts to monitor progress.

Authors:  H M Chapel; M Small; S Gregory; W B Matthews
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

Review 2.  The immunology of coeliac disease.

Authors:  G J Mantzaris; W M Rosenberg; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.

Authors:  T Yamabe; K Takakura; K Sugie; Y Kitaoka; S Takeda; Y Okubo; K Teshigawara; J Yodoi; T Hori
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

4.  Immunologic abnormalities in chronic fatigue syndrome.

Authors:  N G Klimas; F R Salvato; R Morgan; M A Fletcher
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

5.  Immunohistology of tuberculous adenitis in symptomatic HIV infection.

Authors:  J Y Shen; P F Barnes; T H Rea; P R Meyer
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

6.  Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity.

Authors:  U Fiocco; M Rosada; L Cozzi; C Ortolani; G De Silvestro; A Ruffatti; E Cozzi; C Gallo; S Todesco
Journal:  Ann Rheum Dis       Date:  1993-04       Impact factor: 19.103

7.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

Authors:  T Tanaka; J Kameoka; A Yaron; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

Review 8.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

9.  CD26 induces T-cell proliferation by tyrosine protein phosphorylation.

Authors:  E Muñoz; M V Blazquez; J A Madueño; G Rubio; J Peña
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

10.  CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion.

Authors:  P A Havre; M Abe; Y Urasaki; K Ohnuma; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.